Profound Medical/PROF

$8.29

-2.29%
-
1D1W1MYTD1YMAX

About Profound Medical

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Ticker

PROF

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Arun Menawat

Employees

131

Headquarters

Mississauga, Canada

Profound Medical Metrics

BasicAdvanced
$206M
Market cap
-
P/E ratio
-$1.28
EPS
0.80
Beta
-
Dividend rate
$206M
0.79871
$15.03
$7.02
4.5K
5.41
4.73
1.093
15.779
-47.25%
-59.26%
-54.12%
28.447
4.512
4.539
0.74%
1.26%
-0.48%

What the Analysts think about Profound Medical

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 2 analysts.
92.04% upside
High $18.00
Low $13.85
$8.29
Current price
$15.92
Average price target

Profound Medical Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-321.05% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.9M
-5%
Net income
-$6.1M
-31.46%
Profit margin
-321.05%
-27.85%

Profound Medical Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.45%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.35
-$0.26
-$0.42
-$0.26
-
Expected
-$0.35
-$0.34
-$0.32
-$0.28
-$0.29
Surprise
-1.36%
-22.71%
31.46%
-5.45%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Profound Medical stock?

Profound Medical (PROF) has a market cap of $206M as of May 18, 2024.

What is the P/E ratio for Profound Medical stock?

The price to earnings (P/E) ratio for Profound Medical (PROF) stock is 0 as of May 18, 2024.

Does Profound Medical stock pay dividends?

No, Profound Medical (PROF) stock does not pay dividends to its shareholders as of May 18, 2024.

When is the next Profound Medical dividend payment date?

Profound Medical (PROF) stock does not pay dividends to its shareholders.

What is the beta indicator for Profound Medical?

Profound Medical (PROF) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Profound Medical stock price target?

The target price for Profound Medical (PROF) stock is $15.92, which is 92.04% above the current price of $8.29. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Profound Medical stock

Buy or sell Profound Medical stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing